TY - JOUR
T1 - Sarcomatoid mesothelioma
T2 - Future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease
AU - Galetta, Domenico
AU - Catino, Annamaria
AU - Misino, Andrea
AU - Logroscino, Antonio
AU - Fico, Maria
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Malignant pleural mesothelioma (MPM) is the most frequent pleural neoplasm, with asbestos exposure as one of the recognized carcinogen agents, causative in 80% of cases. The prognosis is poor; median survival of untreated cases is 6-9 months, with fewer than 5% of patients surviving 5 years. Sarcomatoid mesothelioma (SM) represents the subtype with the worst outcome and median survival ranging from 3.5 to 8 months. In the last few years, an accurate differentiation between the subtypes of MPM has become a crucial issue, due to differences in chemosensitivity and clinical outcome, and several studies have evaluated different immunohistochemical markers to better define the diagnosis. The different and worse outcome of patients with SM and, in general, nonepithelioid subtypes makes it intriguing to select these cases to better study the biomolecular profile in order to find factors linked to prognosis and/or predictive of therapeutic response. Considering recent studies on miRNA and genetic mapping, further investigation of this rare subtype might represent a field for basic and clinical-translational research providing for more tailored therapies.
AB - Malignant pleural mesothelioma (MPM) is the most frequent pleural neoplasm, with asbestos exposure as one of the recognized carcinogen agents, causative in 80% of cases. The prognosis is poor; median survival of untreated cases is 6-9 months, with fewer than 5% of patients surviving 5 years. Sarcomatoid mesothelioma (SM) represents the subtype with the worst outcome and median survival ranging from 3.5 to 8 months. In the last few years, an accurate differentiation between the subtypes of MPM has become a crucial issue, due to differences in chemosensitivity and clinical outcome, and several studies have evaluated different immunohistochemical markers to better define the diagnosis. The different and worse outcome of patients with SM and, in general, nonepithelioid subtypes makes it intriguing to select these cases to better study the biomolecular profile in order to find factors linked to prognosis and/or predictive of therapeutic response. Considering recent studies on miRNA and genetic mapping, further investigation of this rare subtype might represent a field for basic and clinical-translational research providing for more tailored therapies.
KW - MiRNA
KW - Sarcomatoid mesothelioma
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=84969246703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969246703&partnerID=8YFLogxK
U2 - 10.5301/tj.5000364
DO - 10.5301/tj.5000364
M3 - Article
C2 - 26108245
AN - SCOPUS:84969246703
VL - 102
SP - 127
EP - 130
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 2
ER -